Improving Tolerability and Quality of Life in Pancreatic Cancer Treatment with Atebimetinib

In this discussion panel with Pharmacy Times, Meredith Pelster, MD, MSCI, associate director of GI cancer research at Sarah Cannon Research Institute and a medical oncologist at SCRI Oncology Partners, and Ben Zeskind, PhD, CEO and co-founder of Immuneering, discuss the development of a patient-friendly treatment regimen for pancreatic cancer that includes atebimetinib. The panel explains how modifying chemotherapy dosing to an every-other-week schedule may improve tolerability compared with standard regimens. They note that less frequent chemotherapy may reduce common toxicities such as cytopenias and peripheral neuropathy, while atebimetinib has demonstrated a favorable tolerability profile. The discussion highlights how combining improved chemotherapy scheduling with atebimetinib may help patients stay on therapy longer.